These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 19436656)
1. Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Melandri G; Vagnarelli F; Calabrese D; Semprini F; Nanni S; Branzi A Vasc Health Risk Manag; 2009; 5(1):249-56. PubMed ID: 19436656 [TBL] [Abstract][Full Text] [Related]
2. "Tenecteplase--the best among the equals.". Saran RK; Sethi R; Nagori M Indian Heart J; 2009; 61(5):454-8. PubMed ID: 20635761 [TBL] [Abstract][Full Text] [Related]
4. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction. Dunn CJ; Goa KL Am J Cardiovasc Drugs; 2001; 1(1):51-66. PubMed ID: 14728052 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of tenecteplase in acute myocardial infarction. Guerra DR; Karha J; Gibson CM Expert Opin Pharmacother; 2003 May; 4(5):791-8. PubMed ID: 12740001 [TBL] [Abstract][Full Text] [Related]
6. Tenecteplase: new preparation. Another thrombolytic agent for myocardial infarction: a slightly simpler treatment. Prescrire Int; 2002 Jun; 11(59):83-4. PubMed ID: 12068843 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Tanswell P; Modi N; Combs D; Danays T Clin Pharmacokinet; 2002; 41(15):1229-45. PubMed ID: 12452736 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Wallentin L; Goldstein P; Armstrong PW; Granger CB; Adgey AA; Arntz HR; Bogaerts K; Danays T; Lindahl B; Mäkijärvi M; Verheugt F; Van de Werf F Circulation; 2003 Jul; 108(2):135-42. PubMed ID: 12847070 [TBL] [Abstract][Full Text] [Related]
9. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. Giugliano RP; Roe MT; Harrington RA; Gibson CM; Zeymer U; Van de Werf F; Baran KW; Hobbach HP; Woodlief LH; Hannan KL; Greenberg S; Miller J; Kitt MM; Strony J; McCabe CH; Braunwald E; Califf RM; J Am Coll Cardiol; 2003 Apr; 41(8):1251-60. PubMed ID: 12706917 [TBL] [Abstract][Full Text] [Related]
10. Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis. Giraldez RR; Wiviott SD; Nicolau JC; Mohanavelu S; Morrow DA; Antman EM; Giugliano RP Drugs; 2009 Jul; 69(11):1433-43. PubMed ID: 19634922 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. Sinnaeve PR; Alexander JH; Bogaerts K; Belmans A; Wallentin L; Armstrong P; Adgey JA; Tendera M; Diaz R; Soares-Piegas L; Vahanian A; Granger CB; Van De Werf FJ Am Heart J; 2004 Jun; 147(6):993-8. PubMed ID: 15199346 [TBL] [Abstract][Full Text] [Related]
12. Patency trials with reteplase (r-PA): what do they tell us? Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406 [TBL] [Abstract][Full Text] [Related]
14. Off-target effects of thrombolytic drugs: apolipoprotein A-I proteolysis by alteplase and tenecteplase. Gomaraschi M; Ossoli A; Vitali C; Pozzi S; Vitali Serdoz L; Pitzorno C; Sinagra G; Franceschini G; Calabresi L Biochem Pharmacol; 2013 Feb; 85(4):525-30. PubMed ID: 23219857 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146 [TBL] [Abstract][Full Text] [Related]
16. Tenecteplase for the treatment of acute ischemic stroke: A review of completed and ongoing randomized controlled trials. Coutts SB; Berge E; Campbell BC; Muir KW; Parsons MW Int J Stroke; 2018 Dec; 13(9):885-892. PubMed ID: 30035698 [TBL] [Abstract][Full Text] [Related]